An ongoing clinical study is evaluating the efficacy of anti-CSF1R (pexidartinib) in combination with anti-PD-L1 (durvalumab) in advanced/metastatic CRC or pancreatic cancer (NCT02777710). This evidence concerns the gene CD274 and colorectal carcinoma.